Henry Schein (HSIC) has a number of vital developments. This includes securing exclusive distributor rights for
Curodont, a combatant against tooth decay.
HSIC was also listed as the preferred provider of
Curodont to
Dental Service Organizations. The company has also launched new products and services. Furthermore, they have unveiled several promising initiatives, such as participating in the FDI World Dental Congress in
Istanbul. The company has managed to surpass estimates in their Q2 earnings, but they have cut their annual profit outlook due to a lingering effect of a past cyberattack. Their financial performance in 2024 was generally solid, despite facing ongoing challenges. The company continues to fully integrate its recent acquisition of
TriMed, Inc.. There are some concerns about
HSIC's increasing debt burden and the company's ability to allocate capital. Additionally,
HSIC hosted a ribbon cutting ceremony, celebrating the opening of a new southwestern distribution center. The company's admission to the
extremity segment of the orthopedic market is being watched with interest. A latest sustainability report issued by HSIC indicates significant development in their corporate citizenship efforts.
Henry Schein HSIC News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Sat, 21 Sep 2024 08:09:20 GMT -
Rating 2
- Innovation -2
- Information 5
- Rumor -1
